Cardiol Therapeutics Inc.
CRDL · XNASCIK 1702123fmd_0Z8N496ZPM67YR877W89YEQKTBManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Dec 31, 2025, 6 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | – | 0 | – | – | – | – |
| Research and development | 11 | 11 | 19 | 14 | 14 | 14 |
| Operating income | (21) | (39) | (41) | (30) | (40) | (34) |
| Income tax expense | 0 | 0 | 0 | – | – | – |
| Net income | (21) | (32) | (31) | (28) | (37) | (34) |
| Net income to common shareholders | (21) | (32) | – | – | – | – |